Drug Trial Radar · NCT05484414
Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Dec 30, 2021
Primary completion
Nov 6, 2023
Study completion Nov 6, 2023
Sponsor
- Lead sponsor
- South Rampart Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two-part randomized, double-blind, placebo-controlled study.
Conditions
- Pain
Interventions
SRP-3D (diethylamide)Drug
SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
PlaceboDrug
Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: The time of providing written informed consent until 30 days after the last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences-Miami, Inc.
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.